All times listed are Central European Time (CET)

9:20 am Chair’s Opening Remarks

Maintaing Reliable Supplies & Forging Stronger Supply Chains

10:00 am 100% Assured Supply — 212Pb from Simple Generators Based on a Naturally-occuring Parent (228Th)

  • Julian Kelly Founder & Executive Director, Isoclide Medical

Synopsis

  • Evaluating 212Pb, a naturally-occurring radioisotope, via its parent isotope 228Th for which supply can be assured indefinitely, and from a range of sources that do not depend on expensive accellerator or nuclear reactor infrastructure
  • A prototype 212Pb generator with a size of a small bar-refrigerator has been built in Australia — it is being tested with the vision of fabricating further units to serve RIT communities world-wide

10:20 am The ISOLPHARM Project: New Production Method of High Specific Activity Beta-emitting Radionuclides

Synopsis

  • Analysing the feasibility study for an innovative technology for the production of extremely high specific activity beta emitting radionuclides as radiopharmaceutical precursors
  •  Obtaining radiopharmaceuticals, which is impossible in most cases through standard production facilities (neutron reactors or cyclotrons), at a lower cost to traditional techniques and with a reduced environmental impact
  •  Discussing the production of 111Ag in carrier-free form, at a high production rate and high purity, that enhances the efficiency of biomolecule radiolabeling

10:40 am Nuclear Medicine Innovation: Synergy of competences

  • James Nagarajah Assistant Professor , Radboud University Medical Centre (Radboudumc), The Netherlands Department of Radiology and Nuclear Medicine

Synopsis

  • The clinical challenges
  • Securing availability of resources

11:00 am Live Presenter Q&A

11:15 am Virtual Networking Break

11:45 am Round Table Discussion: Breaking Down the Supply & Fulfilment Pathway Challenges

Synopsis

This interactive session will require delegates to discuss creative solutions to old problems. Using a supply chain diagram, highlight and illustrate the problems that currently exist in the system and come up with an idea, process or other solution that could streamline this issue.

12:15 pm Current Radioisotope Stockpiles & Sourcing/Production Methods

  • Joao Osso Section Head , International Atomic Energy Authority (IAEA)

Synopsis

  • Reviewing the role of IAEA on the production of medical radioisotopes and radiopharmaceuticals
  • Evaluating current supply of medical radioisotopes
  • Exploring routes to produce medical radioisotopes
  • Discussing IAEA activities related to the production of medical radioisotopes and radiopharmaceuticals

12:35 pm Live Presenter Q&A

Securing Funding to Protect & Drive Future Research

12:40 pm Le Chatelier – Don’t Leave Anyone Behind During Radiopharmaceutical Development

Synopsis

  • Securing the right investor for the right radiopharmaceutical assets
  • Budget tailoring for effective development
  • Reviewing trigger points, mile stones and highlights in pharmaceutical development

1:00 pm Panel Discussion: Opening Up About Funding Challenges in Radiopharmaceuticals

Synopsis

  • Highlight issues ranging from funding sources to approaching potential investors
  • Assess the landscape of potential funding sources

1:30 pm Virtual Networking Break

Establishing Criteria for the Novel Targets that the Next Generation of Medical Radionuclides will Target

2:30 pm Panel Discussion: Beyond PSMA – How Do We Realistically Identify New Targets to Take on with Radioligand Therapy

  • Chris Leamon Indiana Site Head, Vice President of Discovery Research, Advanced Accelerator Applications
  • Dale Ludwig Chief Science & Technology Officer, Actinium Pharmaceuticals

Synopsis

  • The success of Lutathera has re-demonstrated the value of RLT and provided another the proof of concept for this drug modality
  • It is essential for the industry to maintain this momentum and look to the future and find the next generation of targets so that we can properly assess their potential value
  • This session therefore covers how researchers are breaking new ground and taking risks on untested targets and indications; as well as picking apart the targets that big pharma has previously taken on with other therapeutics and yielded little success

3:15 pm PARP Targeted Auger Electrons: Nanometre Scale Radiotherapy

  • Thomas Reiner Associate Member, Department of Radiology Chemical Biology Program Memorial Sloan Kettering Cancer Center

Synopsis

  • Reviewing PARP enzymes; established druggable targets that are overexpressed in many cancer types
  • Exploring how Auger electrons can be delivered directly to chromatin via PARP1 binding for cancer cell kill, whilst non-chromatin bound auger emission has minimal biological effect due to being out of range
  • Highlighting how combination therapy offers a wide range of exciting mechanisms to potentiate background DNA damage levels in tumour deposits prior to treatment with PARP targeted auger therapy

3:35 pm Progress in Targeted Alpha-particle Therapies – Our Clinical Experience & Regulatory Perspective

3:55 pm Live Presenter Q&A

4:05 pm Chair’s Closing Remarks & End of Conference